Abiopharma

Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment.?It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19,?and the potential to use?similar?compounds?as pharmaceutical products?against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

Additional info from NASDAQ:
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment.?It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19,?and the potential to use?similar?compounds?as pharmaceutical products?against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

Additional info from OTC:
Zentek Ltd. is a Canadian advanced materials and critical minerals company. It owns the Albany Graphite Project, an igneous-hosted graphite deposit in Northern Ontario held through its wholly owned subsidiary Albany Graphite Corp., where independent bench-scale testing has purified material to 99.9992% carbon at 2.60 ppm equivalent boron. Graphite is designated a critical mineral by both Canada and the United States Department of Energy. Zentek also develops graphene-enabled coatings, including ZenGUARD™ air filtration technology, now selling in Canada and the United States, and holds an aptamer discovery platform through Triera Biosciences Ltd. Head office: Guelph, Ontario. TSXV: ZEN.